The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

Vinay Prasad leaves FDA apparently due to backlash from the agency's handling of potential deaths related to Sarepta's ...

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

Experts say the system of EDRDs incentivizes companies to manufacture these drugs due to the high prices that can be charged for them.

Q2 2025 Earnings Call Transcript July 29, 2025 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is ...

When parts of the nervous system start to break down—or get broken—the consequences for human health can be staggering. Can ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

The U.S. Food and Drug Administration's top official, Vinay Prasad, has left the agency after nearly three months as Director ...

Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to ...

Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as ...

(The Center Square) — Colorado experts and policy groups have had mixed reactions to President Donald Trump’s executive order that signals a stark departure from “Housing First” homelessness ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You ...